- Home
- MGNX vs ATRA Comparison
MGNX vs ATRA Comparison
Compare MGNX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- ATRA
- Stock Information
- Founded
- MGNX 2000
- ATRA 2012
- Country
- MGNX United States
- ATRA United States
- Employees
- MGNX N/A
- ATRA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNX Health Care
- ATRA Health Care
- Exchange
- MGNX Nasdaq
- ATRA Nasdaq
- Market Cap
- MGNX 99.7M
- ATRA 97.0M
- IPO Year
- MGNX 2013
- ATRA 2014
- Fundamental
- Price
- MGNX $1.50
- ATRA $12.04
- Analyst Decision
- MGNX Hold
- ATRA Strong Buy
- Analyst Count
- MGNX 6
- ATRA 3
- Target Price
- MGNX $3.20
- ATRA $21.00
- AVG Volume (30 Days)
- MGNX 828.6K
- ATRA 56.5K
- Earning Date
- MGNX 11-04-2025
- ATRA 11-12-2025
- Dividend Yield
- MGNX N/A
- ATRA N/A
- EPS Growth
- MGNX N/A
- ATRA N/A
- EPS
- MGNX N/A
- ATRA 0.56
- Revenue
- MGNX $165,495,000.00
- ATRA $188,667,000.00
- Revenue This Year
- MGNX N/A
- ATRA N/A
- Revenue Next Year
- MGNX N/A
- ATRA N/A
- P/E Ratio
- MGNX N/A
- ATRA $21.68
- Revenue Growth
- MGNX 303.47
- ATRA 202.41
- 52 Week Low
- MGNX $0.99
- ATRA $5.01
- 52 Week High
- MGNX $4.39
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- MGNX 43.25
- ATRA 42.83
- Support Level
- MGNX $1.30
- ATRA $10.53
- Resistance Level
- MGNX $1.69
- ATRA $12.89
- Average True Range (ATR)
- MGNX 0.11
- ATRA 1.26
- MACD
- MGNX -0.02
- ATRA -0.27
- Stochastic Oscillator
- MGNX 31.01
- ATRA 34.06
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).